Japan's MHLW names Tomonori Nakayama to key reimbursement post

Japan PM Abe

Japan's Ministry of Health, Labor and Welfare (MHLW) announced a series of in-house moves that include naming Tomonori Nakayama as pharmaceutical management director at the Health Insurance Bureau's Medical Economics Division, a key post that advises on price reforms.

The bureau advises Japan's Central Social Insurance Medical Council known as Chuikyo. Nakayama was previously director of the Office of Review Management at the Pharmaceuticals and Medical Devices Agency (PMDA).

The reimbursement agency has been a focal point for the government led by Prime Minister Shinzo Abe to curb growing drug costs with a focus on best-selling newer therapies and a push to use more generic medicines.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The previous holder of the post, Kiyohito Nakai, was seconded to the National Cancer Center.

In other moves, Health Minister Yasuhisa Shiozaki retained Vice Health Minister Kazuo Futagawa in the top civil service post as well as Kazuhiko Mori, the councilor in charge of pharmaceuticals at the minister’s Secretariat.

Starting this week, Shiozaki has separated the Pharmaceutical Safety and Environmental Health Bureau’s Evaluation and Licensing Division into separate units with responsibility for drug and medical device reviews respectively.

Yasuhiro Suzuki, director general for technology policy coordination, will assume the role of director general of the Health Insurance Bureau. The current bureau chief, Takeshi Karasawa, will move to the Cabinet Secretariat.

In other appointments, Daisaku Sato will move to the post of director of the Pharmaceutical Safety and Environmental Health Bureau’s Safety Division with responsibility for medical database MID-NET, from his role as head of the PMDA’s Office of Cellular and Tissue-based Products.

Shiozaki also appointed Atsushi Ichinose as chief of the Blood and Blood Products Division of the Pharmaceutical Safety and Environmental Health Bureau, while Keiko Morimitsu was named to helm the Health Policy Bureau’s Research and Development Division, with a bill on clinical research rules now before parliament as part of her remit.

- here's the MHLW website

Suggested Articles

Acadia's knew it had a winner in psychosis when it called off a trial for its Nuplazid. Now analysts are seeing a blockbuster in the making.

Sandoz would still consider acquisitions, as long as they fit the Novartis unit's focus on generics and biosimilars, CEO Richard Saynor said.

Novartis is planning 80 major drug submissions in key markets over the next three years, and 25 of those could be blockbuster opportunities.